Learn about SPRAVATO® (esketamine) nasal spray, a prescription medicine for two indications. See full Prescribing & Safety Info, including BOXED WARNINGS.

Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO ® is only available through a restricted program called the SPRAVATO ® Risk Evaluation and Mitigation Strategy (REMS) Program.

Learn about SPRAVATO® (esketamine) CIII nasal spray, a prescription medicine for two indications. See full Prescribing & Safety Info, including BOXED WARNINGS.

SPRAVATO ® offers a different approach and is the only FDA-approved nasal spray treatment for treatment-resistant depression (TRD)

Getting Started on SPRAVATO ® If you have treatment-resistant depression (TRD), you may benefit from taking SPRAVATO ® with or without an oral antidepressant. Start the conversation with your doctor to see if adding SPRAVATO ® may be right for you, and discover more about what the full SPRAVATO ® treatment experience could look like for you.

The key steps are outlined below, from how to get started on SPRAVATO®, to ways to pay for your treatment, and what you can expect on your treatment journey.

SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO ® is only available through a restricted program called the SPRAVATO ® Risk Evaluation and Mitigation Strategy (REMS) Program.

You may be eligible for the SPRAVATO withMe Savings Program if you: Are age 18 or older, use commercial or private health insurance for your prescribed SPRAVATO®, and must pay an out-of-pocket cost for your medication. Are enrolled in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Learn more at SpravatoREMS.com/Patients.html.

Find a nearby SPRAVATO ® treatment center and be prepared with our list of common insurance questions relating to SPRAVATO ® coverage. Plus, learn how you could benefit from our patient support program (if you qualify), SPRAVATO withMe, as well as access SPRAVATO ® educational resources like informative FAQs, our patient brochure and more.

ketamine groups compared to the placebo group. The 112 mg dose of intranasal SPRAVATO was associated with significantly higher scores for “Hallucinating,” “Floating,” “Detached,” and “Spaced Out” than the 84 mg dose of intrana